How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
Would you consider holding, deferring, or skipping treatment?
For hepatitis, how would determine if toxicity was immunotherapy vs chemotherapy related?
Community PollStarted
In the event of liver toxicity while treating advanced Hodgkin lymphoma with nivo + AVD, what is your general course of action?
72 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Texas Southwestern Medical Center
Answered on
BV-AVD-related transaminitis is relatively common; however, even with Nivo-AVD, transaminitis is frequently observed, albeit at a lower frequency. Most of these events are self-limited and grade 1-2. Depending on the stage and severity of the event, dose holds can be employed; however, adverse event...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · The University of Texas MD Anderson Cancer Center
Answered on
Agree with Dr. @Dr. First Last.
I have swapped BV for Nivo in some settings. Depends on lab findings and the clinical picture though.
Join for free or sign in to see the full answer